Search results for "Positive"

showing 10 items of 1875 documents

B?cells are not required for T?cell priming in low zone tolerance to contact allergens and contact hypersensitivity

2004

Low zone tolerance (LZT) to contact allergens is induced by epicutaneous exposure to haptens in subsensitizing doses resulting in an inhibition of contact hypersensitivity (CHS), which, in contrast, occurs after sensitization with immunogenic doses of allergens. Performing the protocol of tolerance induction resulted in robust LZT to allergens in B cell-deficient mice in vivo, indicating that B cells are not required for the induction and effector phase of LZT. However, CHS reactions in vivo were restricted in B cell-deficient mice as compared to wild-type (WT) mice. In contrast, analysis of hapten-specific T cell activation in vitro revealed a strong proliferative response of T cells deriv…

Adoptive cell transfermedicine.medical_treatmentT cellImmunologyPriming (immunology)Picryl ChlorideCD8-Positive T-LymphocytesBiologyDermatitis ContactLymphocyte ActivationInterferon-gammaMiceAdjuvants ImmunologicImmune TolerancemedicineAnimalsImmunology and AllergySensitizationB cellCell ProliferationMice KnockoutB-Lymphocytesintegumentary systemInterleukinsOxazoloneAllergensAdoptive TransferMice Inbred C57BLTolerance inductionCytokinemedicine.anatomical_structureImmunologyLymph NodesCD8European Journal of Immunology
researchProduct

The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer

2019

There is no sufficient evidence to establish a standard of care for patients with brain metastases (BM) from HER2Data of 154 patients were retrospectively collected at 14 Italian institutions through a specifically designed database.Median overall survival (OS) was 24.5 months. Patients receiving surgery/stereotactic radiosurgery experienced longer OS compared to those receiving whole-brain radiotherapy or no treatment (33.5 vs. 11.4 months; hazard ratio = 0.34; 95% confidence interval, 0.22-0.52; P .001). Interestingly, whole-brain radiotherapy did not improve OS compared to no treatment (11.4 vs. 9.8 months; hazard ratio = 0.99; 95% confidence interval, 0.62-1.62; P = .99). HER2-targeted …

Adult0301 basic medicineCancer Researchmedicine.medical_specialtymedicine.medical_treatmentSocio-culturaleBreast NeoplasmsLapatinibTreatment experiencedRadiosurgerySRS03 medical and health sciences0302 clinical medicineBreast cancerTrastuzumabInternal medicineHER2 Positive Breast CancerBiomarkers TumormedicineHumansAgedRetrospective Studiesbusiness.industryLapatinibTrastuzumabMiddle AgedWBRTPrognosismedicine.diseaseCombined Modality TherapyConfidence intervalSurvival RateRadiation therapyLapatinib SRS Surgery Trastuzumab WBRT030104 developmental biologyReceptors EstrogenOncology030220 oncology & carcinogenesisLapatinib; SRS; Surgery; Trastuzumab; WBRTSurgeryFemaleNeoplasm Recurrence LocalbusinessFollow-Up Studiesmedicine.drugClinical Breast Cancer
researchProduct

Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study

2018

Abstract Background Retrospective data suggest better outcomes for patients with double hormonal receptor (oestrogen [ER] and progesterone receptor [PgR])–positive (dHR+) early breast cancer, compared with single hormonal receptor–positive, sHR+, (ER+/PgR– or ER–/PgR+) disease. Here, we evaluate the classification according to intrinsic subtypes and clinical outcomes of sHR+ versus dHR+ in HER2-negative breast cancer patients enrolled in GEICAM/9906 study ( NCT00129922 ). Methods Archival tumours were retrieved retrospectively for the analysis of ER, PgR and HER2 status and classified into intrinsic subtypes using the PAM50 gene expression assay. Disease-free survival (DFS) and overall surv…

Adult0301 basic medicineOncologyendocrine systemCancer Researchmedicine.medical_specialtyPaclitaxelBreast NeoplasmsDisease-Free Survival03 medical and health sciencesBreast cancer0302 clinical medicineBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsProgesterone receptormedicineHumansPAM50Single receptor positiveskin and connective tissue diseasesReceptorCyclophosphamideAgedEpirubicinProportional Hazards ModelsRandomized Controlled Trials as TopicRetrospective StudiesHormone receptor positivebusiness.industryIncidence (epidemiology)Hazard ratioLuminal aMiddle Agedmedicine.disease030104 developmental biologyClinical Trials Phase III as TopicReceptors EstrogenOncologyIntrinsic subtypesHormone receptor030220 oncology & carcinogenesisFemaleFluorouracilReceptors ProgesteroneTranscriptomebusinesshormones hormone substitutes and hormone antagonistsHormoneEuropean Journal of Cancer
researchProduct

Endocarditis due to Abiotrophia defectiva, a biofilm-related infection associated with the presence of fixed braces

2017

Abstract Rationale: Endocarditis with Abiotrophia defectiva represents 4.3% to 6% of all streptococcal endocarditis. The article presents diagnosis issues and the complexity of the treatment. Patient concerns: We present the case of a female white patient, aged 26 years, who developed infectious endocarditis caused by A defectiva, in the last trimester of pregnancy, a biofilm-related infection associated with the presence of fixed braces. Diagnoses: The diagnosis of infectious endocarditis was confirmed by the cardiac ultrasound examination that revealed a voluminous vegetation on the mitral valve, and acute mitral regurgitation caused by chordae tendinae rupture, and also by isolating Abio…

Adult0301 basic medicinemedicine.medical_specialtyProsthesis-Related Infectionsmedicine.drug_classmedicine.medical_treatment030106 microbiologyAntibioticsbiofilm03 medical and health sciences0302 clinical medicinePregnancyAbiotrophiaMitral valvemedicineHumansEndocarditisClinical Case Report030212 general & internal medicinePregnancy Complications InfectiousAbiotrophia defectivaGram-Positive Bacterial InfectionsAbiotrophia defectivaBracesinfectious endocarditisbiology4900business.industryMitral valve replacementEndocarditis BacterialGeneral MedicineAbiotrophiabiology.organism_classificationmedicine.diseaseSurgerymedicine.anatomical_structureEmbolismBiofilmsInfective endocarditisFemalebusinessResearch ArticleMedicine
researchProduct

Study of T-cell activation in Type I diabetic patients and pre-Type I diabetic subjects by cytometric analysis: Antigen expression defectin vitro

1993

In Type I diabetes the observation of a decreased release of interleukin-2 (IL-2) and soluble IL-2 receptors by means of stimulated lymphocytes in vitro indicates that a primary immunoregulatory defect may be involved. To confirm this hypothesis we investigated the T-cell activation trend, evaluating the surface expression of IL-2 receptor (CD25), transferrin (CD71), HLA class II (DR), and CD69 phenotypes after in vitro stimulation with phytohemagglutinin (PHA; 1 and 10 micrograms/ml) and concanavalin A (12.5 micrograms/ml) in six newly diagnosed Type I diabetics and six islet cell- and insulin autoantibody-positive first-degree relatives. As controls were studied six long-standing Type I d…

AdultAntigens Differentiation T-LymphocyteCD4-Positive T-LymphocytesMaleInterleukin 2medicine.medical_specialtyTime FactorsAdolescentCD3 ComplexCD8 AntigensT-Lymphocytesmedicine.medical_treatmentT cellImmunologyTransferrin receptorBiologyLymphocyte ActivationAntigenAntigens CDInternal medicineDiabetes mellitusReceptors TransferrinmedicineHumansImmunology and AllergyLectins C-TypeIL-2 receptorPhytohemagglutininsReceptorInsulinReceptors Interleukin-2HLA-DR Antigensmedicine.diseaseAntigens Differentiation B-LymphocyteKineticsDiabetes Mellitus Type 1Endocrinologymedicine.anatomical_structureInterleukin-2Femalemedicine.drugJournal of Clinical Immunology
researchProduct

False positive rate of an arrayCGH platform for single-cell preimplantation genetic screening and subsequent clinical application on day-3

2013

In this work, false positive rate of an arrayCGH platform for its use in day-3 single-blastomere analysis was calculated. For this purpose, 38 embryos diagnosed as abnormal on day-3 by FISH were re-biopsied on day-4. Single-cell day-4 arrayCGH diagnosis was then performed. A successful amplification was obtained in 97.4 % (37/38) of the day-4 cells analysed by arrayCGH. Day-3 FISH and day-4 arrayCGH diagnosis were concordant in 35/37 cases. The two discordant embryos were spread and all the cells from each embryo were re-analysed by FISH on day 5. The same error rate (2.7 %) for day-3 FISH and day-4 arrayCGH was obtained when comparing day-5 FISH re-analysis. After this pre-clinical phase, …

AdultBlastomeresmedicine.medical_specialtyTime FactorsPregnancy RateBiopsyConcordanceClinical pregnancyBiologySensitivity and SpecificityMiscarriagePregnancyarrayCGHDay-5 FISH re-analysisGeneticsmedicineChromosomes HumanHumansFalse Positive ReactionsEmbryo ImplantationGenetic TestingProspective StudiesIn Situ Hybridization FluorescenceGenetics (clinical)CryopreservationGynecologyComparative Genomic HybridizationReproducibility of ResultsObstetrics and GynecologyGeneral MedicineAneuploidyEmbryo Transfermedicine.diseaseBlastocystReproductive MedicineBlastomere biopsyBlastomere biopsyFish <Actinopterygii>Day-3 PGSFemaleFalse positive rateDevelopmental Biology
researchProduct

A Randomized Controlled Trial of Continuous Positive Airway Pressure on Glucose Tolerance in Obese Patients with Obstructive Sleep Apnea

2014

Study objectives Obstructive sleep apnea (OSA) is associated with an increased prevalence of metabolic syndrome (MetS), even in patients with morbid obesity. Our goal was to address whether continuous positive airway pressure (CPAP) treatment improved glucose metabolism in this population. Methods A prospective randomized controlled trial was performed in severe OSA patients with morbid obesity without diabetes in two university referral hospitals. Patients received conservative (CT) versus CPAP treatment for 12 weeks. MetS components, homeostasis model assessment of insulin resistance (HOMA-IR) and oral glucose tolerance were assessed at baseline and after treatment. Results A total of 80 …

AdultBlood GlucoseMalemedicine.medical_specialtyglucose tolerancemedicine.medical_treatmentPopulationSettore MED/10 - Malattie Dell'Apparato Respiratorio030204 cardiovascular system & hematologyImpaired glucose tolerance03 medical and health sciences0302 clinical medicineInsulin resistancePhysiology (medical)Internal medicineDiabetes mellitusinsulin resistanceGlucose IntoleranceWeight LossmedicineHumansInsulinProspective StudiesContinuous positive airway pressureeducationobstructive sleep apneaMetabolic SyndromeSleep Apnea Obstructiveeducation.field_of_studyGlucose tolerance testContinuous Positive Airway Pressuremedicine.diagnostic_testbusiness.industryGlucose Tolerance TestMiddle Agedmedicine.diseaseObesity Morbidrespiratory tract diseasesSurgeryObstructive sleep apnea030228 respiratory systemFemaleNeurology (clinical)Insulin ResistanceMetabolic syndromeSleep Disordered Breathingbusinesscontinuous positive airway pressure
researchProduct

Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients

2006

A significant percentage of stage II melanoma patients (tumor thickness >1 mm) remain at risk of tumor recurrence after primary tumor excision. In this study, we used tumor antigen-pulsed dendritic cells as an adjuvant for immunization of these “high-risk” melanoma patients after resection of the primary tumor. A total of 13 patients were included and vaccinated 6 times every 14 days with autologous dendritic cells pulsed with a MelanA/MART-1 peptide in combination with a recall antigen. Antigen-specific immune responses were monitored before, during and up to 1 year after the last vaccination. The majority of patients exhibited increased recall antigen-specific CD4+ T cell responses upon v…

AdultCD4-Positive T-LymphocytesCancer ResearchSkin NeoplasmsT cellCD8-Positive T-LymphocytesCancer VaccinesMART-1 AntigenImmune systemAdjuvants ImmunologicAntigens NeoplasmHumansMedicineMelanomaCell Proliferationbusiness.industryMelanomaVaccinationDendritic CellsDendritic cellmedicine.diseasePrimary tumorTumor antigenNeoplasm ProteinsTreatment Outcomemedicine.anatomical_structureddc: 610OncologyImmunizationImmunologybusinessCD8International Journal of Cancer
researchProduct

CD1a down-regulation in primary invasive ductal breast carcinoma may predict regional lymph node invasion and patient outcome.

2008

AIMS: CD1a is a molecule belonging to the highly conserved group of CD1 proteins. Its expression in dendritic cells is related to the presentation of tumour-derived glycolipid antigens to T cells and, consequently, the development of a successful antitumour response. The aim was to investigate the presence of CD1a+ cells in both primary tumours and lymph nodes (LN) of a series of 35 invasive ductal carcinomas by both immunohistochemistry and reverse transcription-polymerase chain reaction. METHODS AND RESULTS: CD1a antigen was more expressed in N0 than N1 breast cancer (P < 0.0001) in both primary lesions and LN metastases and correlated positively and significantly with oestrogen (ER) (P =…

AdultCD4-Positive T-LymphocytesCarcinoma Ductal BreastDown-RegulationBreast NeoplasmsDendritic CellsCD8-Positive T-LymphocytesMiddle AgedCD1APrognosisImmunohistochemistryAntigens CD1Gene Expression Regulation NeoplasticReceptors EstrogenPredictive Value of TestsLymphatic MetastasisHumansFemaleReceptors ProgesteroneAged
researchProduct

SARS-CoV-2-specific Cell-mediated Immunity in Kidney Transplant Recipients Recovered From COVID-19.

2021

BACKGROUND: The magnitude and kinetics of severe acute respiratory syndrome coronavirus 2-specific cell-mediated immunity (SARS-CoV-2-CMI) in kidney transplant (KT) recipients remain largely unknown. METHODS: We enumerated SARS-CoV-2-specific interferon-I³-producing CD69+ CD4+ and CD8+ T cells at months 4 and 6 from the diagnosis of coronavirus disease 2019 (COVID-19) in 21 KT recipients by intracellular cytokine staining. Overlapping peptides encompassing the SARS-CoV-2 spike (S) glycoprotein N-terminal 1- to 643-amino acid sequence and the membrane protein were used as stimulus. SARS-CoV-2 IgG antibodies targeting the S1 protein were assessed by ELISA at month 6. RESULTS: Detectable (≥0.1…

AdultCD4-Positive T-LymphocytesGraft RejectionMalemedicine.medical_specialty030230 surgeryCD8-Positive T-LymphocytesAntibodies Monoclonal HumanizedGastroenterology03 medical and health sciencesImmunocompromised HostInterferon-gamma0302 clinical medicineCOVID-19 TestingImmunityInternal medicinemedicineHumansInterferon gammaskin and connective tissue diseasesKidney transplantationAgedTransplantationImmunity Cellularbiologybusiness.industrySARS-CoV-2CD69COVID-19Middle Agedmedicine.diseaseKidney TransplantationTacrolimusTransplant RecipientsCOVID-19 Drug TreatmentMonoclonalbiology.protein030211 gastroenterology & hepatologyFemaleAntibodybusinessCD8Immunosuppressive Agentsmedicine.drugFollow-Up StudiesTransplantation
researchProduct